March 19, 2020 / 10:08 AM / 21 days ago

BRIEF-Soligenix Announces Positive Top-Line Results For Its Pivotal Phase 3 Flash Trial Evaluating Sgx301 In Treatment Of Cutaneous T-Cell Lymphoma

March 19 (Reuters) - Soligenix Inc:

* SOLIGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FOR ITS PIVOTAL PHASE 3 FLASH TRIAL EVALUATING SGX301 IN TREATMENT OF CUTANEOUS T-CELL LYMPHOMA

* SOLIGENIX INC - STATISTICALLY SIGNIFICANT TREATMENT RESPONSE ACHIEVED IN PRIMARY ENDPOINT OF SGX301

* SOLIGENIX INC - SGX301 WAS WELL-TOLERATED AND ITS MECHANISM OF ACTION IS NOT ASSOCIATED WITH DNA DAMAGE LIKE OTHER CURRENTLY AVAILABLE THERAPIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below